Agilent Technologies (NYSE:A) Issues FY 2026 Earnings Guidance

Agilent Technologies (NYSE:A) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 5.900-6.040 for the period, compared to the consensus estimate of 5.930. The company issued revenue guidance of $7.3 billion-$7.5 billion, compared to the consensus revenue estimate of $7.3 billion. Agilent Technologies also updated its Q2 2026 guidance to 1.390-1.420 EPS.

Agilent Technologies Price Performance

Agilent Technologies stock traded down $9.15 during midday trading on Thursday, reaching $115.57. The company’s stock had a trading volume of 2,158,816 shares, compared to its average volume of 2,094,009. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 0.45. The stock has a market cap of $32.69 billion, a PE ratio of 25.27, a price-to-earnings-growth ratio of 3.61 and a beta of 1.30. Agilent Technologies has a 52 week low of $96.43 and a 52 week high of $160.27. The business has a 50-day moving average price of $135.31 and a 200-day moving average price of $135.97.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 earnings per share for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.01). The company had revenue of $1.80 billion during the quarter, compared to analyst estimates of $1.81 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, sell-side analysts predict that Agilent Technologies will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 22nd. Investors of record on Tuesday, March 31st will be issued a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $1.02 annualized dividend and a dividend yield of 0.9%. Agilent Technologies’s dividend payout ratio (DPR) is 22.32%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Robert W. Baird boosted their price target on Agilent Technologies from $142.00 to $165.00 and gave the stock an “outperform” rating in a report on Tuesday, November 25th. Barclays decreased their price objective on shares of Agilent Technologies from $165.00 to $150.00 and set an “overweight” rating for the company in a research report on Thursday. Wells Fargo & Company cut their price target on Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating on the stock in a report on Thursday. Citigroup raised their target price on Agilent Technologies from $165.00 to $185.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Finally, HSBC started coverage on shares of Agilent Technologies in a research note on Tuesday, January 20th. They set a “buy” rating and a $180.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $162.71.

Key Stories Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Management set FY‑2026 revenue of $7.3B–$7.5B and expanded its “Ignite” operating‑system effort aimed at margin improvement — a constructive forward signal that supports medium‑term profit growth. Read More.
• Positive Sentiment: Wall Street remains broadly supportive: the recent analyst coverage shows many buy/overweight ratings and a median price target near $170, leaving upside at current levels if execution continues. Read More.
• Neutral Sentiment: Agilent described Q1 results as largely in‑line with Street expectations and blamed U.S. snowstorms for some top‑line disruption — this helps explain the small miss but leaves mixed signals for investors. Read More.
• Neutral Sentiment: Company Q1 disclosures and the slide deck/earnings call are available for investors who want to assess guidance detail and segment trends before betting on a rebound. Read More.
• Negative Sentiment: Q1 EPS missed by $0.01 and revenue came in slightly below estimates ($1.80B vs. ~$1.81B), which triggered near‑term selling pressure as algos and traders react to the headline misses. Read More.
• Negative Sentiment: Operating cash flow and operating profit showed weakness in the quarter (cash from ops down meaningfully year‑over‑year), a red flag for investors focused on free cash generation and buyback/dividend capacity. Read More.
• Negative Sentiment: Analysts at Wells Fargo and Barclays cut price targets (Wells Fargo $175→$165; Barclays $165→$150) — still overweight, but the trims remove some near‑term bullish momentum and likely contributed to the stock pullback. Read More. Read More.
• Negative Sentiment: Notable insider sales and large institutional portfolio reductions were flagged in the quarter, which can exacerbate selling pressure or signal cautious positioning by some large holders. Read More.

Hedge Funds Weigh In On Agilent Technologies

Institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC raised its holdings in shares of Agilent Technologies by 424.1% in the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock worth $240,956,000 after buying an additional 1,652,244 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Agilent Technologies by 132.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock valued at $277,807,000 after acquiring an additional 1,340,161 shares during the period. Morgan Stanley raised its stake in Agilent Technologies by 15.9% in the 4th quarter. Morgan Stanley now owns 5,041,881 shares of the medical research company’s stock worth $686,049,000 after acquiring an additional 692,202 shares during the last quarter. Invesco Ltd. raised its stake in Agilent Technologies by 32.0% in the 4th quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock worth $352,519,000 after acquiring an additional 627,804 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its position in Agilent Technologies by 639.4% during the 2nd quarter. Lazard Asset Management LLC now owns 678,718 shares of the medical research company’s stock worth $80,093,000 after acquiring an additional 586,931 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.